Fulcrum Therapeutics Inc expected to post a loss of 46 cents a share - Earnings Preview

Fulcrum Therapeutics

12/05/2023 13:55

* Fulcrum Therapeutics Inc  FULC.OQ   FULC.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 15. 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 56.5% decrease in revenue to $1.128 million from $2.59
million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Fulcrum
Therapeutics Inc
is for a loss of 46 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Fulcrum
Therapeutics Inc is $7​, above​ its last closing price of $3.18.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.51       -0.49      -0.50     Missed  -2.1
 Sep. 30 2022  -0.62       -0.61      -0.51     Beat    16.7
 Jun. 30 2022  -0.66       -0.66      -0.83     Missed  -25.6​
 Mar. 31 2022  -0.62       -0.63      -0.64     Missed  -2.1
 ​​Dec.        -0.71       -0.73      -0.58     Beat    20.3
 31 2021                                                
 Sep. 30 2021  -0.62       -0.65      -0.57     Beat    11.9​
 Jun. 30 2021  -0.62       -0.62      -0.60     Beat    3.9
 Mar. 31 2021  -0.65       -0.66      -0.54     Beat    17.8
 This summary was machine generated May 12 at 12:55 GMT.  All
figures in US dollars  unless otherwise stated